Drug Search Results
More Filters [+]

Aleglitazar

Alternative Names: aleglitazar
Latest Update: 2024-02-01
Latest Update Note: PubMed Publication

Product Description

Aleglitazar is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with hypoglycemic activity. Aleglitazar binds to both PPARalpha and PPARgamma and decreases plasma levels of glucose, LDL-C, triglycerides (TG) and increases HDL levels. This agent may be used for the treatment of diabetes and cardiovascular disease. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Aleglitazar)

Mechanisms of Action: PPAR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aleglitazar

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Kidney Failure, Chronic|Type 2 Diabetes|Acute Coronary Syndrome

Phase 2: Heart Failure|Kidney Diseases|Type 2 Diabetes|Insulin Resistance|Myocardial Ischemia|Coronary Artery Disease

Phase 1: Healthy Volunteers|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Alerenal Study

P3

Withdrawn

Type 2 Diabetes|Kidney Failure, Chronic

2019-01-01

BC28027

P3

Completed

Type 2 Diabetes

2013-11-01

BC22140

P3

Completed

Type 2 Diabetes|Acute Coronary Syndrome

2013-11-01

YC28037

P3

Completed

Type 2 Diabetes

2013-11-01

Recent News Events